Document:

<PAGE>
                                                                     EXHIBIT 4.1

                                  PROVANT, INC.

                      1998 NON-QUALIFIED STOCK OPTION PLAN

                       As amended through January 18, 2002

1.  PURPOSE

         The purpose of this 1998 Non-Qualified Stock Option Plan (the "Plan")
is to advance the interests of PROVANT, Inc. (the "Company") by enhancing the
ability of the Company and its subsidiaries to attract and retain employees,
consultants or advisers who are in a position to make significant contributions
to the success of the Company, to reward them for their contributions and to
encourage them to take into account the long-term interests of the Company.

         The Plan provides for the award of options to purchase shares of the
Company's common stock ("Stock"). Options granted pursuant to the Plan shall be
non-qualified options and not incentive stock options as defined in Section 422
of the Internal Revenue Code of 1986.

2.  ELIGIBILITY FOR AWARDS

         Persons eligible to receive awards under the Plan shall be all
employees, consultants and advisers of the Company and its subsidiaries who, in
the opinion of the Board, are in a position to make a significant contribution
to the success of the Company and its subsidiaries. Except for awards covering
no more than 25,000 shares of Stock in the aggregate, directors and officers of
the Company shall not be eligible to receive awards under the Plan. A subsidiary
for purposes of the Plan shall be a corporation in which the Company owns,
directly or indirectly, stock possessing 50% or more of the total combined
voting power of all classes of stock. Persons selected for awards under the Plan
are referred to herein as "participants".

3.  ADMINISTRATION

         The Plan shall be administered by the Board of Directors (the "Board")
of the Company. The Board shall have authority, not inconsistent with the
express provisions of the Plan, (a) to grant awards consisting of options to
such participants as the Board may select; (b) to determine the time or times
when awards shall be granted and the number of shares of Stock subject to each
award; (c) to determine the terms and conditions of each award; (d) to prescribe
the form or forms of any instruments evidencing awards and any other instruments
required under the Plan and to change such forms from time to time; (e) to
adopt, amend and rescind rules and regulations for the administration of the
Plan; and (f) to interpret the Plan and to decide any questions and settle all
controversies and disputes that may arise in connection with the Plan. All
exercises of the foregoing authority by the Board shall be conclusive and shall
bind all parties. Subject to Section 8, the Board shall also have the authority,
both generally and in particular instances, to waive compliance by a participant
with any obligation to be performed by the participant under an award, to waive
any condition or provision of an award, and to amend or cancel any award (and if
an award is canceled, to grant a new award on such terms as the Board
<PAGE>
shall specify), except that the Board may not take any action with respect to an
outstanding award that would adversely affect the rights of the participant
under such award without such participant's consent. Nothing in the preceding
sentence shall be construed as limiting the power of the Board to make
adjustments required by Section 5(c) and Section 6(i).

         The Board may, in its discretion, delegate some or all of its powers
with respect to the Plan to a committee (the "Committee"), in which event all
references in this Plan (as appropriate) to the Board shall be deemed to refer
to the Committee. A majority of the members of the Committee, if one is
appointed, shall constitute a quorum. Any determination of the Committee under
the Plan may be made without notice or meeting of the Committee by a writing
signed by a majority of the Committee members.

4.  EFFECTIVE DATE AND TERM OF PLAN

         The Plan shall become effective on the date on which it is approved by
the Board.

         No awards shall be granted under the Plan after the completion of ten
years from the date on which the Plan was adopted by the Board, but awards
previously granted may extend beyond that date.

5.  SHARES SUBJECT TO THE PLAN

         (a) Number of Shares. Subject to adjustment as provided in Section
5(c), the aggregate number of shares of Stock that may be delivered upon the
exercise of awards granted under the Plan shall be 2,900,000 shares. If any
award granted under the Plan terminates without having been exercised in full,
or upon exercise is satisfied other than by delivery of Stock, the number of
shares of Stock as to which such award was not exercised shall be available for
future grants within the limits set forth in this Section 5(a).

         (b) Shares to be Delivered. Shares delivered under the Plan shall be
authorized but unissued Stock or, if the Board so decides in its sole
discretion, previously issued Stock acquired by the Company and held in its
treasury. No fractional shares of Stock shall be delivered under the Plan.

         (c) Changes in Stock. In the event of a stock dividend, stock split or
combination of shares, recapitalization or other change in the Company's capital
stock, the number and kind of shares of Stock subject to awards then outstanding
or subsequently granted under the Plan, the exercise price of such awards, the
maximum number of shares of Stock that may be delivered under the Plan, and
other relevant provisions shall be appropriately adjusted by the Board, whose
determination shall be binding on all persons.

         The Board may also adjust the number of shares subject to outstanding
awards and the exercise price and the terms of outstanding awards to take into
consideration material changes in accounting practices or principles,
extraordinary dividends, consolidations or mergers (except those described in
Section 6(i)), acquisitions or dispositions of stock or property or any other
event if it is determined by the Board that such adjustment is appropriate to
avoid distortion in the operation of the Plan.

                                      -2-
<PAGE>
6.  TERMS AND CONDITIONS OF OPTIONS

         (a) Exercise Price of Options. The exercise price of each option shall
be determined by the Board but shall not be less, in the case of an original
issue of authorized stock, than par value.

         (b) Duration of Options. Options shall be exercisable during such
period or periods as the Board may specify. The latest date on which an option
may be exercised (the "Final Exercise Date") shall be the date that is ten years
from the date the option was granted or such earlier date as the Board may
specify at the time the option is granted.

         (c) Exercise of Options.

                  (i)      Options shall become exercisable at such time or
                           times and upon such conditions as the Board shall
                           specify. In the case of an option not immediately
                           exercisable in full, the Board may at any time
                           accelerate the time at which all or any part of the
                           option may be exercised.

                  (ii)     Options may be exercised only in writing. Written
                           notice of exercise must be signed by the proper
                           person and furnished to the Company, together with
                           (A) such documents as the Board requires and (B)
                           payment in full as specified below in Section 6(d)
                           for the number of shares for which the option is
                           exercised.

                  (iii)    The delivery of Stock upon the exercise of an option
                           shall be subject to compliance with (A) applicable
                           federal and state laws and regulations, (B) if the
                           outstanding Stock is at the time listed on any stock
                           exchange, the listing requirements of such exchange,
                           and (C) Company counsel's approval of all other legal
                           matters in connection with the issuance and delivery
                           of such Stock. If the sale of Stock has not been
                           registered under the Securities Act of 1933, as
                           amended, the Company may require, as a condition to
                           exercise of the option, such representations or
                           agreements as counsel for the Company may consider
                           appropriate to avoid violation of such Act and may
                           require that the certificates evidencing such Stock
                           bear an appropriate legend restricting transfer.

                  (iv)     The Board shall have the right to require that the
                           participant exercising the option remit to the
                           Company an amount sufficient to satisfy any federal,
                           state, or local withholding tax requirements (or make
                           other arrangements satisfactory to the Company with
                           regard to such taxes) prior to the delivery of any
                           Stock pursuant to the exercise of the option. If
                           permitted by the Board, either at the time of the
                           grant of the option or the time of exercise, the
                           participant may elect, at such time and in such
                           manner as the Board may prescribe, to satisfy such
                           withholding obligation by (A) delivering to the
                           Company Stock (which in the case of Stock acquired
                           from the Company shall have been owned by the
                           participant for at least six months prior to the
                           delivery date, unless the Board otherwise determines)
                           having a fair market value equal

                                      -3-
<PAGE>
                           to such withholding obligation, or (B) requesting
                           that the Company withhold from the shares of Stock to
                           be delivered upon the exercise a number of shares of
                           Stock having a fair market value equal to such
                           withholding obligation.

                  (v)      If an option is exercised by the executor or
                           administrator of a deceased participant, or by the
                           person or persons to whom the option has been
                           transferred by the participant's will or the
                           applicable laws of descent and distribution, the
                           Company shall be under no obligation to deliver Stock
                           pursuant to such exercise until the Company is
                           satisfied as to the authority of the person or
                           persons exercising the option.

         (d) Payment for and Delivery of Stock. Stock purchased upon exercise of
an option under the Plan shall be paid for as follows:

                  (i)      in cash or by personal check, certified check, bank
                           draft or money order payable to the order of the
                           Company; or

                  (ii)     if so permitted by the Board, (A) through the
                           delivery of shares of Stock (which, in the case of
                           Stock acquired from the Company, shall have been held
                           for at least six months prior to delivery) having a
                           fair market value on the last business day preceding
                           the date of exercise equal to the purchase price or
                           (B) by delivery of a promissory note of the
                           participant to the Company, such note to be payable
                           on such terms as are specified by the Board or (C) by
                           delivery of an unconditional and irrevocable
                           undertaking by a broker to deliver promptly to the
                           Company sufficient funds to pay the exercise price or
                           (D) by any combination of the permissible forms of
                           payment.

         (e) Rights as Shareholder. A participant shall not have the rights of a
shareholder with regard to awards under the Plan except as to Stock actually
received by the participant under the Plan.

         (f) Nontransferability of Awards; Restrictions on Stock. Except as the
Board may otherwise determine, no award may be transferred other than by will or
by the laws of descent and distribution, and during a participant's lifetime an
award may be exercised only by the participant.

         The Board, in its discretion, may at the time an award is granted make
Stock delivered under the award subject to such restrictions and conditions,
including restrictions on resale and buy-back rights, as it deems appropriate.

         (g) Death. Except as otherwise provided in the award by the Board at
the time of grant, if a participant dies, each option held by the participant
that was not then exercisable shall terminate and each option that was
exercisable immediately prior to death may be exercised by the participant's
executor or administrator or by the person or persons to whom the option is
transferred by will or the applicable laws of descent and distribution, at any
time within the one-

                                      -4-
<PAGE>
year period (or such longer or shorter period as the Board may determine)
beginning with the date of the participant's death but in no event beyond the
Final Exercise Date.

         (h) Termination of Service other than by Death. Except as otherwise
provided in the award by the Board at the time of grant, if an employee's
employment with the Company and its subsidiaries terminates for any reason other
than by death, all options held by the employee that are not then exercisable
shall terminate and options that are exercisable on the date employment
terminates shall continue to be exercisable for 90 days, or such shorter or
longer period as the Board may determine, but in no event beyond the Final
Exercise Date.

         In the case of a participant who is not an employee, provisions
relating to the exercisability of options following termination of service shall
be specified in the award. If not so specified, all options held by such
participant that are not then exercisable shall terminate upon termination of
service. Options that are exercisable on the date the participant's service as a
consultant or adviser terminates shall continue to be exercisable for 90 days,
or such shorter or longer period as the Board may determine, but in no event
beyond the Final Exercise Date.

         (i) Merger, Consolidation, Asset Sale, Liquidation, etc.
Notwithstanding any other provisions of the Plan, in the event that a
transaction occurs that results in the Stock not being registered under Section
12 of the Securities Exchange Act of 1934, as amended, all options shall
terminate upon the completion of the transaction. If the transaction is intended
to be treated as a pooling of interests for accounting purposes, the Board shall
cause the acquiring or surviving corporation or one of its affiliates to grant
replacement options to participants. In all other transactions, the Board may
either arrange for replacement options, accelerate the exercisability of all
outstanding options (subject to completion of the transaction) or terminate all
options in exchange for a cash payment.

         The Company may grant options under the Plan in substitution for
options held by employees of another corporation who become employees of the
Company, or a subsidiary of the Company, as the result of a merger or
consolidation of the employing corporation with the Company or a subsidiary of
the Company, or as a result of the acquisition by the Company, or one of its
subsidiaries, of property or stock of the employing corporation. The Company may
direct that substitute options be granted on such terms and conditions as the
Board considers appropriate in the circumstances.

7.  EMPLOYMENT RIGHTS

         Neither the adoption of the Plan nor the grant of awards shall confer
upon any participant any right to continue as an employee of, or consultant or
adviser to, the Company or any subsidiary of the Company or affect in any way
the right of the Company or any such subsidiary to terminate his or her
employment by the Company or any subsidiary of the Company at any time. Except
as specifically provided by the Board in any particular case, the loss of
existing or potential profit in awards granted under this Plan shall not
constitute an element of damages in the event of termination of the relationship
of a participant even if the termination is in violation of an obligation of the
Company or any subsidiary of the Company to the participant by contract or
otherwise.

                                      -5-
<PAGE>
8.   EFFECT, DISCONTINUANCE, CANCELLATION, AMENDMENT AND TERMINATION

         Neither adoption of the Plan nor the grant of awards to a participant
shall affect the Company's right to make awards to such participant that are not
subject to the Plan, to issue to such participant Stock as a bonus or otherwise,
or to adopt other plans or arrangements under which Stock may be issued.

         The Board may at any time discontinue granting awards under the Plan.
With the consent of the participant (except as otherwise provided in the Plan),
the Board may at any time cancel an existing award in whole or in part and grant
another award for such number of shares as the Board specifies. The Board may at
any time or times amend the Plan or any outstanding award for the purpose of
satisfying changes in applicable laws or regulations or for any other purpose
that may at the time be permitted by law, or may at any time terminate the Plan
as to further grants of awards, but no such amendment shall adversely affect the
rights of any participant (without the participant's consent) under any award
previously granted.

                                      -6-<PAGE>
Exhibit 10.1               Settlement Agreement, effective October 26,
                           2001, by, between and among the Company, Arthur A.
                           Beisang, Dr. Robert A. Ersek, Arthur A. Beisang, III,
                           M.D., Carbon Medical Technologies, Inc., Brennen
                           Medical, Inc. and Timothy Lawin.

                              SETTLEMENT AGREEMENT

         Effective upon the date of last execution by a party, this Settlement
Agreement ("Agreement") is made by, between and among Uroplasty, Inc.
("Uroplasty"), Arthur A. Beisang ("Beisang"), Dr. Robert Ersek ("Ersek"), Arthur
A. Beisang III, M.D. ("Beisang III"), Carbon Medical Technologies, Inc.
(formerly known as Advanced UroScience, Inc. and referred to as "Carbon Medical"
herein), Brennen Medical, Inc. and Timothy Lawin, hereinafter sometimes
collectively referred to as the "Parties".

                                    RECITALS

         WHEREAS, Uroplasty filed a lawsuit entitled Uroplasty, Inc. v. Advanced
UroScience, Inc., Brennen Medical, Inc. and Timothy Lawin, in Ramsey County
District Court, Court File No. 62-C1-98-008574 (the "First Lawsuit"); and

         WHEREAS, the First Lawsuit was removed to the United States District
Court for the District of Minnesota, Case No. 98-CV-2082 and after proceedings
therein, and in the United States Court of Appeals for the Federal Circuit, was
remanded back to Ramsey County District Court, where it is now pending; and

         WHEREAS, Carbon Medical owns patent number 5,451,406 ("Carbon Medical's
Patent"); and

         WHEREAS, in the First Lawsuit, Uroplasty alleged that Carbon Medical's
Patent derived from technology developed by Uroplasty, and that Carbon Medical,
Brennen Medical, Inc. and Timothy Lawin were liable for breach of contract,
breach of fiduciary duty, and violation of Minnesota's Trade Secret Act; and

         WHEREAS, Carbon Medical, Brennen Medical, Inc. and Timothy Lawin denied
Uroplasty's allegations and asserted counterclaims in the first Lawsuit; and

         WHEREAS, Carbon Medical filed a lawsuit entitled Advanced UroScience,
Inc. v. Arthur A. Beisang, in Ramsey County District, Court File No. CO-99-1626
(the "Second Lawsuit"); and

         WHEREAS, the Second Lawsuit was removed to United States District Court
for the District of Minnesota, Case No. 99-CV-294, where it is now pending; and

         WHEREAS, Uroplasty filed a 37 CFR 1.607 request with the United States
Patent and Trademark Office for an interference ("Interference") between Carbon
Medical's Patent and a September 18, 1996 patent application owned by Uroplasty
entitled "Treatment of Urological Disorders by Injection of Micro Particles"
("Uroplasty's Patent Application"); and

         WHEREAS, Ersek, Beisang and Beisang III are shareholders of Uroplasty
and have claimed intellectual property rights adverse to Carbon Medical, Brennen
Medical, Inc. and/or Lawin; and

<PAGE>

         WHEREAS, the Parties wish to have a complete and full settlement and
resolution of all claims and potential claims between them, including all issues
relating to the claims asserted or which could have been asserted or which could
be asserted in the future, in the First Lawsuit, the Interference, and the
Second Lawsuit; and

                     NOW THEREFORE, IT IS AGREED AS FOLLOWS:

1. Payment: In consideration of the terms and conditions of this Agreement,
Carbon Medical, Brennen Medical, Inc. and Timothy Lawin shall jointly pay the
sum of $400,000 to Uroplasty. $200,000 of this amount will be paid within ten
(10) business days after the effective date of this Agreement or ten (10)
business days after the filing of Uroplasty's written declaration of abandonment
of Uroplasty's Patent Application and withdrawal of its request for
Interference, whichever occurs later; $100,000 will be paid six (6) months after
the first payment; $100,000 will be paid twelve (12) months after the first
payment. Carbon Medical, Brennen Medical, Inc. and Timothy Lawin will pay simple
interest at the rate of 8% per annum on the deferred balances.

2. RELEASE: Upon execution of this Agreement, and for good and valuable
consideration, except for those obligations created by this Agreement, the
Parties do hereby fully, finally and forever release each other and their
respective agents, representatives, employees, shareholders, officers,
directors, attorneys, successors or assigns, divisions, subsidiaries and related
companies, and insurance companies from any and all claims, lawsuits, causes of
action, administrative proceedings, including, without limitation, proceedings
in the United States Patent and Trademark Office, default notices, debts,
accounts receivable, purchase orders, invoices, contracts, duties, accounts,
charges, demands, judgments, representations and warranties of any nature
whatsoever which the Parties have, or ever had, or ever could have had, or may
have in the future arising from or relating to any and all matters preceding the
date of this Agreement, against each other, including, without limitation: those
that were or could have been brought in the First Lawsuit, the Second Lawsuit,
and the Interference; and, all claims falling within the Covenant Not to
Commence Further Proceeding set out in paragraph 3, below. The Parties agree and
acknowledge that this Agreement is supported by adequate consideration, is
freely and voluntarily given, without any duress or coercion, and after the
Parties have consulted with their legal counsel and carefully and completely
read all the terms and provisions of this Agreement.

3. COVENANT NOT TO COMMENCE FURTHER PROCEEDINGS: The Parties, collectively and
individually, hereby covenant that they will not commence any action or lawsuit
in law or in equity or any administrative or other proceeding, including,
without limitation, proceedings in the United States Patent and Trademark
Office, against each other to the extent that such litigation or other
proceeding is within the scope of the release in paragraph 2 of this Agreement
or is otherwise in violation of any of the covenants or undertakings contained
in this Agreement. Uroplasty, Ersek, Beisang and Beisang III, collectively and
individually, also covenant that they will not commence or assist others in the
commencement or prosecution of any legal, administrative or other proceeding
which challenges Carbon Medical's proprietary or other rights to its carbon bead
technology and products, as now or hereafter constituted, including
specifically, but without limitation, filings, applications or proceedings in
the United States Patent and Trademark Office contesting any issued patent or
patent application of Carbon Medical to the extent that such patent or patent
application relates to Carbon Medical's bead technology or products, as now or
hereafter constituted. In addition to any liability that shall accrue upon
breach of this covenant, the breaching party shall pay all reasonable attorneys'
fees and costs incurred by the non-breaching party or parties in defense
thereof.

4. DISMISSAL OF LAWSUITS: Upon execution of this Agreement, counsel for the
appropriate Parties shall execute and cause to be filed with the Ramsey County
District Court a Stipulation for Order dismissing all claims with prejudice in
the First Lawsuit, with the Parties to bear their own costs. Upon execution of
this Agreement, counsel for the appropriate Parties shall also execute and cause
to be filed with the United States District Court a Stipulation for Order
dismissing all claims with prejudice in the Second Lawsuit, with the Parties to
bear their own costs.

5. COVENANT TO ABANDON PATENT APPLICATION: Within five (5) days of execution of
this Agreement, Uroplasty will file in the United States Patent and Trademark
Office a written declaration of abandonment of Uroplasty's Patent Application
and request for Interference and shall not file any continuation, continuation
in part applications or foreign applications based on Uroplasty's Patent
Application. At the same time, Uroplasty shall also execute and cause to be
filed with the United States Patent and Trademark Office a written declaration
of abandonment of any and all United States and foreign applications (if any)
claiming the benefit of the filing date of Uroplasty's Patent Application and a
written withdrawal

<PAGE>

of its request for an Interference with Carbon Medical's Patent. Uroplasty,
Ersek, Beisang and Beisang III agree never to file a request for an Interference
with Carbon Medical's Patent. Uroplasty, Ersek, Beisang and Beisang III also
agree to file a request with the United States Patent and Trademark Office for
entry of an adverse judgment in any interference between a case owned by
Uroplasty, Ersek, Beisang and/or Beisang III and Carbon Medical's Patent within
five (5) days after declaration of any such Interference. If the objectives of
this Agreement cannot otherwise be achieved and if requested to do so by Carbon
Medical, Uroplasty, Ersek, Beisang and Beisang III agree to assign immediately
to Carbon Medical Uroplasty's Patent Application, any and all U.S. and foreign
applications claiming the benefit of the filing date of that application, and
Uroplasty's request for Interference with Carbon Medical's Patent.

6. INDEMNIFICATION FOR FUTURE CLAIMS: Uroplasty agrees to indemnify and hold
Carbon Medical, Brennen Medical, Inc., Timothy Lawin, and their respective
officers, directors, employees, agents, insurers, successors, representatives,
heirs and assigns, and each of them, harmless from any and all manner of loss,
damage, claim, proceeding, award, cost or expense, including, without
limitation, attorneys fees and costs, incurred by them, or any of them, in or in
connection with litigation or any other proceeding of any manner or nature
whatsoever by or on behalf of Uroplasty or their officers, directors, employees,
agents, insurers, successors, representatives, heirs or assigns, including,
without limitation, proceedings brought in the United States Patent and
Trademark Office, to the extent that the subject matter of such litigation or
other proceeding is within the scope of the release in paragraph 2, above, or is
otherwise in violation of any of the covenants or undertakings contained in this
Agreement.

7. SEVERABILITY: If any provision of this Agreement is held by a Court of
competent jurisdiction to be invalid, void, or unenforceable, the remaining
provisions shall nonetheless continue in full force and effect without being
impaired or invalidated in any way.

8. EXECUTION IN COUNTERPARTS: This Agreement may be executed in counterparts,
each of which, when so executed, shall be deemed to be an original, and such
counterparts together shall constitute one and the same instrument.

9. ENTIRE AGREEMENT: This Agreement constitutes the entire understanding among
the Parties hereto and may not be modified, amended or waived, except by an
instrument, in writing, executed by the Party against whom such an amendment,
clarification, or waiver is sought to be enforced. This Agreement was negotiated
among the Parties, represented by their respective counsel, and shall not be
deemed to have been drafted by any Party hereto. The undersigned entered into
this Agreement voluntarily and for reasons of their own doing, and in so doing
have not relied upon any statement or representation of any Party except as set
forth herein.

10. CONFIDENTIALITY: The Parties agree to keep confidential the terms of this
Agreement, other than as necessary to complete their respective obligations
under the Agreement, to enforce this Agreement, and as may be required by 35
U.S.C.ss.135(c).

11. BENEFIT: This Agreement inures to the benefit of and is binding upon the
Parties, as well as their respective representatives, agents, successors, heirs
and assigns.

12. DISPUTES: The Parties agree that they and any disputes arising from this
Agreement will be subject to the exclusive jurisdiction of the United States
District Court, District of Minnesota or Ramsey County District Court, and that
the sole venue for the litigation of such disputes shall be either Court as may
be appropriate. The prevailing party in any such dispute shall be entitled to an
award of reasonable attorney fees and such other relief, in law or equity, to
which that party may be entitled.

IN WITNESS WHEREOF, the Parties have executed this Agreement on the dates
specified below adjacent to their respective signatures.

<PAGE>

UROPLASTY, INC.

By                                              Date of Execution
  -------------------------------------                          ---------------
Its
   ------------------------------------

CARBON MEDICAL TECHNOLOGIES, INC.

By
  -------------------------------------
Its                                             Date of Execution
  -------------------------------------                          ---------------

BRENNEN MEDICAL, INC.

By                                              Date of Execution
  -------------------------------------                          ---------------
Its
  -------------------------------------

                                                Date of Execution
---------------------------------------                          ---------------
Timothy P. Lawin

                                                Date of Execution
---------------------------------------                          ---------------
Robert Ersek, M.D.

                                                Date of Execution
---------------------------------------                          ---------------
Arthur A. Beisang

                                                Date of Execution
---------------------------------------                          ---------------
Arthur A. Beisang III, M.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]